T
he expression "resistant hypertension" (RH) surfaced in the medical literature shortly after antihypertensive therapy first appeared. It was generally understood to mean a lack of response to available pharmacotherapy. In 1978, Gifford and Tarazi, on reviewing the literature and based on their own extensive experience, concluded that RH was a diminishing phenomenon. 1 This, they opined, reflected the fragility of raised blood pressure in the face of increasingly varied and effective antihypertensive agents. A subsequent systematic review of the English language literature identified 37 articles addressing RH that had been published between 1975 and 1985. 2 Of these, 15 provided a quantitative definition of the condition, and only two explored prevalence by providing a denominator. Not surprisingly, most reports used different diagnostic criteria, treatments, and duration to define RH. Altogether, these studies suggested that RH was an uncommon phenomenon.
A 1988 analysis of the one-year experience of 1,781 participants receiving protocol-directed, goal driven, free, and conveniently provided care in New York City revealed "potential" resistancefailure to achieve blood pressure control on two successive visits-in 4.2% of subjects. 2 "Confirmed" RH required treatment with two different agents at both visits. By these stricter criteria, only 2.9% failed to achieve a BP <160/95 mm Hg, or realize a BP reduction of 15% systolic and/or 10% diastolic within the first year of therapy. Most RH was attributed to nonadherence to prescribed therapy, and, to a lesser extent, renal insufficiency.
The ongoing concern about RH probably reflects the perception among experienced physicians that its prevalence is relatively high. However, these early studies provide little support for that notion, and less insight into the current status of RH.
The recent publication of "Resistant Hypertension: Diagnosis, Evaluation, and Treatment, " prepared by The Professional Education Committee of the Council of High Blood Pressure Research of the American Heart Association 3 provides a useful starting point from which to reconsider where RH now stands, define research needs, and describe its place in the context of overall hypertension management. As is often the case when a group of experts examine a murky area to produce a consensus document, the yield was mixed.
The authors caution readers to avoid conflating RH with "uncontrolled" hypertension. Nevertheless, their review of clinical trials and epidemiological studies, by identifying the frequent coexistence of uncontrolled hypertension and multiple drug use, tends to imply a high prevalence of RH.
In reality, the failure to control blood pressure despite the use of three antihypertensive agents is hardly evidence of pharmacological RH. Instead, it might well reflect patient nonadherence or physician selection of inappropriate drugs compounded by an unwillingness to remove those that are ineffective. In short, in the absence of the rigorous therapeutic criteria upon which the diagnosis of real RH must rest, "uncontrolled hypertension" is most likely to reflect inappropriate physician and/or patient behavior, characterized by irrational drug selection, inadequate dose, or lack of patient adherence to drug regimens.
Unfortunately, the AHA Statement does not include a specific guide to drug selection and/or application as needed to achieve maximum therapeutic efficiency. This deficiency, together with the absence of a time frame for appropriate therapy to justify a diagnosis of RH renders their definition of RH too imprecise for use by either researchers or clinicians.
Effective treatment demands a proper match of physiology and pharmacology. All human blood pressure is determined by the interplay of volume and vasoconstriction. Optimal therapy must be based upon assessment of blood pressurecontrol mechanisms in individual patients, and therapies tailored to their needs. Stepwise addition of complementary drugs (without subtraction of ineffective or counterproductive agents) seems to work in about half of patients. But it is only after rational, pathophysiologically guided therapy has been applied, that these "uncontrolled" patients can be classified as having RH. My own view is that assessment of the activity of the renin-angiotensin system provides the mechanistic insights that permit the therapeutic process to be both efficacious and efficient. Drugs must be prescribed in sufficient dose and over a sufficient period of time to assure accurate assessment of response. For diuretics, this may take weeks. Drugs that do not work-or may even raise pressure-should be discontinued. Because the AHA Statement lacks these essential steps it cannot be the basis to define RH. 
EDITORIAL
At the same time, the AHA does serve a useful and valuable purpose. By highlighting the lack of sound epidemiological information about RH, it makes clear the absence of a clear definition of terms and criteria for diagnosis, and signals the need for rigorous prospective populationbased studies to establish the magnitude of the problem, and its determinants and distribution. Finally, and most valuably, it includes a pathway for systematic evaluation of patients with uncontrolled blood pressure. This algorithm can be cast into a formal protocol to guide physicians both within the conventional medical care system and in the supervision of others to extend care beyond its narrow confines. It classifies a series of possible explanations generally detectable by available technology. Some are correctable, others are partially soluble, and some are intractable.
I believe that the AHA Statement is a useful step in prodding us to fresh thinking about treatment that can ultimately lead to a better separation of "uncontrolled" and "resistant" hypertensive patients. The next step is to design a precise modern therapeutic strategy that recognizes the heterogeneity of persons with elevated pressure and permits the matching of drug to patient. Figure 1 provides an approach to all patients that attempts to separate "Pseudo-" and true "RH." "Pseudo resistance" applies to situations in which, at least theoretically, persistent hypertension is within the control of patients and/or physicians. These include nonadherence, inappropriate therapy, and interfering substances. Lifestyle factors a real test of optimal therapy. My guess is that a formal epidemiological study, based on effective application of a rational therapeutic strategy and careful monitoring of adherence, will result in finding only a very small fraction to be truly RH. These few are nevertheless well worth finding; a better understanding of their phenotypes and genotypes could yield clues that enhance understanding of the pathophysiology of all types of hypertension.
rarely, by themselves, render proper antihypertensive therapy ineffective-just harder. Reducing alcohol, weight, and/or salt, which are always difficult to achieve, can sometimes overcome seemingly intractable hypertension. Traditional forms of secondary hypertension are uncommon and, even when present and irreversible, are not usually resistant to appropriate pharmacological intervention. Correction of adrenal or renovascular disease will often normalize blood pressure, or at least reduce the number and/or dose of antihypertensive agents required. Less is known about prevalence, diagnosis, and treatment of obstructive sleep apnea-related hypertension-a relative newcomer to the list of secondary forms of hypertension.
The real value of this pathway will be measured by how much the current 50% control rate of treated hypertensive patients can be improved. The label of true RH should be reserved for those who fail 
